StoryFunding
Cambrian Bio awarded $30.8M from ARPA-H's PROSPR program for selective mTORC1 inhibitor
Cambrian Bio's TORnado platform was awarded up to $30.8M from ARPA-H's PROactive Solutions for Prolonging Resilience (PROSPR) program. The funding supports development of selective mTORC1 inhibitors aimed at preserving intrinsic capacity (physical and metabolic resilience) in aging populations while avoiding side effects from mTORC2 inhibition.